New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work.

Gestalt Diagnostics (Spokane, WA, USA) has released the Mitotic Counting algorithm which has been trained on more than 100,000 individual mitosis and across seven scanner models. The algorithm performs impressively with an F1-Score of 0.74, matching the performance of top-of-the-line methods in the field. The algorithm is currently available in the Gestalt AI Studio for use on a variety of cancers including cutaneous mast cell tumors, breast cancer, lymphoma, lung cancer, melanoma, neuroendocrine, colon cancer, and bladder carcinoma. The algorithm has been trained on several scanner models, including those from Hamamatsu, Leica, 3D Histech, and Aperio.

Key to the broad applicability of deep learning algorithms is their ability to adapt to new scanners and different types of tissue; a broad dataset is crucial to achieve this goal. Gestalt Diagnostics' dataset encompasses seven types of tissues spanning eight tumors and is digitized with seven different scanner models. Additionally, Gestalt Diagnostics also offers PathFlow, a smart and customizable workflow solution that offers genuine interoperability for optimal efficiency. This solution supports both digital and glass slides and allows for tailored rules that can be can be configured to meet specific needs and requirements.

"What does this mean for our customers? Confidence,” said Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. “Gestalt is focused on providing solutions that provide a foundation of confidence in use as this industry continues to evolve, innovate, and incorporate products that are meant to enhance a pathologist's or scientist's daily life."

"We are extremely proud of the comprehensive approach we take to AI development as an organization,” added Brian Napora, Gestalt VP, AI Solutions. “Our position is to not only look at development and training with a small subset of images or on one or two scanners, that would not prove as effective or accurate as we feel our customers and the industry require. Therefore, we train on tens of thousands images, tumors cells, or in this case, mitosis and multiple scanner models across several scanner vendors to ensure the most accurate, clinically usable options for our customers."

Related Links:
Gestalt Diagnostics

Visit expo >

Platinum Supplier

ADAMTS-13 Protease Activity Test

ATS-13 Activity Assay

New

Gold Supplier

hCG Whole Blood Pregnancy Test

VEDALAB hCG-CHECK-1

POCT Fluorescent Immunoassay Analyzer

FIA Go

New

Virus/Pathogen Kits

QIAsymphony DSP